title: The reply.
authors.affiliation: Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Marc
authors.initials: M
authors.lastname: Carrier
authors.affiliation: Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
authors.forename: Alok A
authors.initials: AA
authors.lastname: Khorana
authors.affiliation: Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Zwicker
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications*; D011322:Primary Prevention / Q000379:methods*; D054556:Venous Thromboembolism / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants